Recombinant Human GM2A Protein，His

GM2A, or GM2 activating protein, plays a crucial role in the metabolism of GM2 gangliosides, which are glycosphingolipids found in the nervous system. The study of GM2A is particularly important due to its association with GM2 ganglioside accumulation in lysosomal storage disorders, such as GM2 gangliosidoses, which include Tay-Sachs disease and Sandhoff disease. These conditions are characterized by the deficiency of specific hexosaminidase enzymes, leading to harmful levels of GM2 in the body, particularly affecting neuronal function and resulting in severe neurological symptoms. Understanding the structure and function of GM2A can provide insights into the molecular mechanisms underlying these disorders, potentially facilitating the development of therapeutic strategies. Researchers have focused on GM2A's role as a cofactor in the enzymatic degradation of GM2 gangliosides, enhancing the activity of hexosaminidase enzymes. Furthermore, GM2A's interactions with other cellular components and lipid membranes are of significant interest, as they may influence the lysosomal pathway and ganglioside metabolism. Advances in recombinant protein technology have enabled the production of GM2A for in vitro studies, allowing for detailed investigations of its biochemical properties, stability, and functionality. Such research is vital for elucidating the pathophysiology of GM2-related diseases and may ultimately lead to innovative treatment methods, including enzyme replacement therapies or gene therapies aimed at restoring normal metabolic function in affected individuals. As our understanding of GM2A and its mechanisms improves, it holds promise for addressing the challenges posed by GM2 gangliosidoses and enhancing patient outcomes.